Particle.news
Download on the App Store
4 ARTICLES
·
last wk.

Investor Firms Urge Cytokinetics Shareholders to Seek Lead Role in FDA-Disclosure Suit Before Nov. 17

The suit targets alleged misstatements on aficamten’s FDA timing, including the NDA’s filing without a REMS.

Overview

  • Rosen Law Firm, Pomerantz LLP, Kahn Swick & Foti, and Faruqi & Faruqi are inviting investors to move for lead-plaintiff status by November 17, 2025.
  • The federal securities class action is pending in the Northern District of California as Seidman v. Cytokinetics, Inc., No. 25-cv-07923.
  • The alleged class period runs from December 27, 2023 through May 6, 2025, covering purchases of Cytokinetics securities on NASDAQ.
  • Plaintiffs allege the company misled investors about the expected approval timeline for aficamten and failed to disclose risks tied to submitting the NDA without a REMS.
  • Disclosures in May 2025 included an FDA PDUFA extension to December 26, 2025 for REMS review and a CEO acknowledgment of the initial filing without a REMS, after which shares fell about 13% on May 2 and 7% on May 6.